One Child Required Every Compatible Blood Unit Available Nationwide

Nine-year-old Qasim Rizwan from Bolton developed autoimmune haemolytic anaemia, a condition in which the immune system destroys red blood cells faster than the body can replace them. His red-cell profile was exceptionally difficult to match.

NHS Blood and Transplant specialists identified a rare combination that included r’r’, a Rhesus-system phenotype reported in approximately one person in 10,000. The report states that only around 50 UK donors have this phenotype.

The matching units were not simply “rare blood” in general. They were units compatible with Qasim’s particular antigen profile. NHSBT sent every matching frozen unit held in the national bank. His mother said that once the stored blood had been used, the team had to contact a compatible donor directly.

The transfused cells were also being destroyed rapidly. Treatment therefore required more than transfusion alone and included steroids and immunoglobulin. Qasim recovered and later visited the national frozen blood bank team that helped save him.

How many cases never become headlines?

The published report does not provide a national count of patients for whom the full compatible reserve is exhausted. It reports approximately 1,200 UK cases of autoimmune haemolytic anaemia each year, but only a small and undefined proportion will combine severe haemolysis with such a rare compatibility profile.

That missing number matters. Patients with rare phenotypes, multiple antibodies or a history of repeated transfusion may require highly selected units. The system can search rare-donor registries, thaw frozen blood and call donors urgently, but each step requires time and the right inventory.

We need to develop the bridge

Compatible donor blood remains essential. It provided functions that saved this child and should not be minimized. But the case shows why donor blood cannot be the only layer of preparedness for every rare or complex emergency.

This is the bridge-solution question. It does not mean replacing transfusion, immune treatment or the rare-donor system. It means adding another layer between the beginning of oxygen-delivery failure and the arrival of definitive compatible treatment.

We have discussed rare blood as an exceptional problem for decades. The practical next step is to define the bridge scientifically: which patients, which physiological trigger, which duration, which safety endpoints and how the product would integrate with transfusion and disease-specific treatment.